Ventilator Associated PneumoniaNCT07116382
Risk Factors of Ventilator-Associated Pneumonia in Critically Ill Population of Alexandria
An observational study of Ventilator Associated Pneumonia, run by Suez Canal University at 1 site in Egypt.
Trial summary
The aim of the study is to compare cases of ventilator-associated pneumonia with matched controls of mechanically ventilated patients to identify any relevant independent risk factors for ventilator-associated pneumonia. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Ventilator Associated Pneumonia
- How many people
- 180 participants
- Where
- 1 siteEgypt
- Study dates
- 20 Feb 2025to 20 May 2025
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Adults diagnosed with VAP (cases group) and matched controls without VAP.
Who may be able to join
- All adult (≥ 18 years) mechanically ventilated patients > 48 hours who are diagnosed with VAP (Case Group).
- The control group is mechanically ventilated (≥ 48 hours) patients and matched with cases regarding their gender, age, and duration of MV.
Who cannot join
- Patients with pneumonia prior to MV and those developing pneumonia within 48 hours are excluded from the study.
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Risk Factors of Ventilator-Associated Pneumonia in Critically Ill Population of Alexandria; Case-Control Study
The aim of the study is to compare cases of ventilator-associated pneumonia with matched controls of mechanically ventilated patients to identify any relevant independent risk factors for ventilator-associated pneumonia. All adult (≥ 18 years) mechanically ventilated patients > 48 hours who are diagnosed with ventilator-associated pneumonia are considered as cases. The control group are mechanically ventilated patients and matching with cases regarding their age, gender, and duration of mechanical ventilation.
Read the detailed description
Ventilator-associated pneumonia is associated with long hospital stays and significant costs. It also prolongs the length of mechanical ventilation. Incidences of ventilator associated pneumonia are highly influenced by the characteristics of the patient population studied and the criteria and techniques applied for diagnosis. The reported incidence is ranged between 10-20% of mechanically ventilated patients. This incidence in developed countries differs significantly from that in developing ones due to many reasons. Several risk factors are identified. The risk factors can be host, device, or personnel related. The most reproducible risk factor is the duration of mechanical ventilation.
The most well recognized modifiable risk factors are mainly intervention related causes. Despite widespread ventilator-associated pneumonia prevention efforts, there was a 35% increase in the ventilator associated events between 2019 and 2020. Since critically ill patients are dynamic patients who are in need to multiple interventions and techniques, revisiting the risk factors of VAP is essential.
Despite widespread prevention efforts, VAP prevention bundles, surveillance systems and updating definitions by CDC, there was a 35% increase in the ventilator associated events between 2019 and 2020 according to CDC healthcare associated infections progress report in 2020. Since critically ill patients are dynamic patients who are in need to multiple interventions and techniques, revisiting the modifiable risk factors of VAP is essential.
- Conditions
- Ventilator Associated Pneumonia
- Keywords
- Critical Care, Ventilator Associated Pneumonia, Risk Factors
- Medical subject headings
- Pneumonia, Ventilator-Associated
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| VAP group | All adult (≥ 18 years) mechanically ventilated patients > 48 hours who are diagnosed with ventilator-associated pneumonia are considered as cases. All possible risk factors for VAP are investigated. | |
| Matched Control group | Mechanically ventilated (≥ 48 hours) patients and matching with cases regarding their age, gender, and duration of MV. All possible risk factors for VAP are investigated. |
What is being measured
The primary outcome is the main question the study is designed to answer.
In-ICU mortality
All-Cause Mortality Rate
Measured: Up to ICU discharge for a maximum of 3 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted11 Aug 2025
- Study start20 Feb 2025
- Primary completion20 May 2025
- Study completion20 May 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Ventilator Associated PneumoniaStudies of the same condition, open and under way.
- More trials run by Suez Canal UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case-control
- Time perspective
- Retrospective
- Enrolment
- 180 participants (actual)
Sponsor and investigators
- Lead sponsor
- Suez Canal University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, islam elsayed, Suez Canal University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07116382
- Sponsor's protocol ID
- VAPRISK
- Status last verified
- Aug 2025
- First submitted
- 2 Aug 2025
- Last updated
- 11 Aug 2025
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 11 Aug 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Risk Factors of Ventilator-Associated Pneumonia in Critically Ill Population of Alexandria; Case-Control Study
- ClinicalTrials.gov ID
- NCT07116382
- Acronym / sponsor ID
- VAPRISK
- Conditions
- Ventilator Associated Pneumonia
- Keywords
- Critical Care, Ventilator Associated Pneumonia, Risk Factors
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 180 participants (actual)
- Lead sponsor
- Suez Canal UniversityUniversity, hospital or other
- Study start
- 20 Feb 2025 (actual)
- Primary completion
- 20 May 2025 (actual)
- Study completion
- 20 May 2025 (actual)
- First posted
- 11 Aug 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The aim of the study is to compare cases of ventilator-associated pneumonia with matched controls of mechanically ventilated patients to identify any relevant independent risk factors for ventilator-associated pneumonia. All adult (≥ 18 years) mechanically ventilated patients > 48 hours who are diagnosed with ventilator-associated pneumonia are considered as cases. The control group are mechanically ventilated patients and matching with cases regarding their age, gender, and duration of mechanical ventilation.
Detailed description
Ventilator-associated pneumonia is associated with long hospital stays and significant costs. It also prolongs the length of mechanical ventilation. Incidences of ventilator associated pneumonia are highly influenced by the characteristics of the patient population studied and the criteria and techniques applied for diagnosis. The reported incidence is ranged between 10-20% of mechanically ventilated patients. This incidence in developed countries differs significantly from that in developing ones due to many reasons. Several risk factors are identified. The risk factors can be host, device, or personnel related. The most reproducible risk factor is the duration of mechanical ventilation.
The most well recognized modifiable risk factors are mainly intervention related causes. Despite widespread ventilator-associated pneumonia prevention efforts, there was a 35% increase in the ventilator associated events between 2019 and 2020. Since critically ill patients are dynamic patients who are in need to multiple interventions and techniques, revisiting the risk factors of VAP is essential.
Despite widespread prevention efforts, VAP prevention bundles, surveillance systems and updating definitions by CDC, there was a 35% increase in the ventilator associated events between 2019 and 2020 according to CDC healthcare associated infections progress report in 2020. Since critically ill patients are dynamic patients who are in need to multiple interventions and techniques, revisiting the modifiable risk factors of VAP is essential.
Study design
- Observational model
- Case-control
- Time perspective
- Retrospective
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| VAP group | – | –All adult (≥ 18 years) mechanically ventilated patients > 48 hours who are diagnosed with ventilator-associated pneumonia are considered as cases. All possible risk factors for VAP are investigated. |
| Matched Control group | – | –Mechanically ventilated (≥ 48 hours) patients and matching with cases regarding their age, gender, and duration of MV. All possible risk factors for VAP are investigated. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Adults diagnosed with VAP (cases group) and matched controls without VAP.
Key inclusion criteria (2 listed)
- All adult (≥ 18 years) mechanically ventilated patients > 48 hours who are diagnosed with VAP (Case Group).
- The control group is mechanically ventilated (≥ 48 hours) patients and matched with cases regarding their gender, age, and duration of MV.
Key exclusion criteria (1 listed)
- Patients with pneumonia prior to MV and those developing pneumonia within 48 hours are excluded from the study.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
In-ICU mortality
Time frame: Up to ICU discharge for a maximum of 3 months
All-Cause Mortality Rate
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 11 Aug 2025.
Related trials for Ventilator Associated Pneumonia
Not yet recruitingObservational study
Traditional Chinese Medicine in Multidrug-Resistant Bacterial Pneumonia
Multi Drug Resistant Infections, Pneumnia
Not yet recruitingObservational study
Early Identification of Pathogens in Children With Respiratory Tract Infection by Mechanical Ventilation Using mNGS
VAP - Ventilator Associated Pneumonia
RecruitingPhase 4
EaRly impAct theraPy With Ceftazidime-avibactam Via rapID Diagnostics
Blood Stream Infections, Ventilator Associated Pneumonia
Recruiting
Immediate Versus Substantiated Antibiotic Therapy in Suspected Non-Severe Ventilator-Associated Pneumonia
Ventilator-Associated Pneumonia (VAP)
Not yet recruiting
Mobile-Based Microlearning for Improving ICU Nurses' Adherence to Ventilator-Associated Pneumonia Prevention Protocols
Ventilator-Associated Pneumonia
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Ventilator Associated Pneumonia, run by Suez Canal University at 1 site in Egypt.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 11 Aug 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
In-ICU mortality (time frame: Up to ICU discharge for a maximum of 3 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 11 Aug 2025; AzTrials last refreshed its copy on 8 Nov 2026.